Printer-friendly versionPrinter-friendly version

Combined hepatitis B vaccines

Monday, October 22, 2001

Session 1 Opening and objectives

Chair: Peter Grob and André Meheus 09.00-09.15

  • Welcome.
  • Introduction of the participants.
  • Objectives of the meeting:
    1. Take stock of the currently available/licensed combined hepatitis B vaccines in the European countries;
    2. Review the data on the hexavalent HB-Hib-DTPa-IPV vaccines: safety, immunogenicity, license, and availability in Europe;
    3. Update the information on future combined hepatitis B vaccines;
    4. Review the infant immunisation schedules in Europe;
    5. Discuss the impact of the availability of combined hepatitis B vaccines on the hepatitis B immunisation programmes in Europe;
    6. Discuss the added value of combined hepatitis B vaccines in a global perspective.
  • Review of the meeting programme.
  • Combined hepatitis B vaccines: an overview of the situation - Pre-meeting document. 93 Kb (.doc)

Session 2 Vaccination schedules and programmes

Chair: Peter Grob and André Meheus 9.15-9.30
Overview of the vaccination programme in Malta. 125 Kb (.ppt)
Mark Muscat (Public Health Department, Malta)

9.30-9.40
Countries in Europe where combined vaccines are licensed. 27 Kb (.ppt)
Pierre Van Damme (VHPB)

9.40–10.00
Infant and adolescent vaccination schedules in Europe - anno 2001. 86 Kb (.ppt)
Nicole Guérin (Comité Technique Vaccinations, France)

10.00-10.20
Infant and adolescent hepatitis B vaccination and use of combination vaccines - USA. 229 Kb (.ppt)
Fred Shaw (CDC, USA)

10.20–11.15
Feedback from the respective countries: The use of combined vaccines in universal vaccination programmes, for individuals or selected groups, … - Recent or future changes in vaccination schedules due to the availability of combined vaccines.
All

11.15-11.45
Coffee break

11.45-12.30
Harmonisation of vaccination calendars in the European countries: pros and cons.
Michael Pfleiderer (Paul-Ehrlich-Instititut, Germany)

12.30-14.00
Lunch

Session 3 Current and new combined vaccines

Chair: Johannes Hallauer and Colette Roure

14.00-14.20
European regulatory authorities' perspective and view on proving safety and immunogenicity of combined vaccines - General aspects - Recent experiences. 61 Kb (.ppt)
Michael Pfleiderer (Paul-Ehrlich-Institute, Germany)

14.20-14.40
Combined vaccines with a hepatitis B component - The role of non-clinical testing in ensuring their safety and efficacy. 360 Kb (.ppt)
Roland Dobbelaer (Scientific Institute of Public Health, Belgium)

14.40–14.50
Discussion.

14.50–15.10
New vaccine supply and financing: a case study of combination vaccines in developing countries. 417 Kb (.ppt)
Susan McKinney (WHO, Switzerland)

15.10–15.20
Discussion.

15.20-15.40
Influence of combined vaccines on infant immunisation coverage – Recent data from Italy [Factors influencing vaccine uptake in Italy], Germany [Germany: recommendations and delivery of vaccines], and Belgium [Analysis of factors influencing vaccine uptake: perspectives from Belgium]. 1,098 Kb (.ppt)
Paolo Bonanni (University of Florence, Italy)

15.40-15.50
Discussion.

15.50-16.20
Coffee break

16.20-17.30
Round table discussion: a global perspective on combined vaccines.
Combined vaccines now and in the future; What do we need from a public health point of view? Pros and cons for industrialised countries and developing countries? What is being developed: a perspective from the industry?
Moderators: André Meheus(University of Antwerpen, Belgium) and Andrei Lobanov (WHO, Denmark)

17.30-18.00

Special Session

Chair: Paolo Bonanni and Peter Grob:
Feedback on 'Peter Grob et al. Laboratory surveillance, screening, and diagnostics of HBV infection. 2001', in preparation.

18.00
Close of the day by the chair - Housekeeping announcements.

  Tuesday, October 23, 2001

Session 4 Combined vaccines: where is the limit?

Chair: Wolfgang Jilg and Daniel Shouval 9.00-9.40
Hepatitis B vaccination: an alternative (re)view. 984 Kb (.ppt)
Geert Leroux-Roels (Ghent University, Belgium)

9.40-9.50
Discussion.

9.50-10.05
Importance of combined hepatitis B vaccines - Point of view of a paediatrician. 187 Kb (.ppt)
Vytautas Usonis (Vilnius University Centre of Paediatrics, Lithuania)

10.05-10.50
Immunogenicity profile of combined vaccines in infants. 508 Kb (.ppt)
Helena Käyhty (National Public Health Institute, Finland)

10.50-11.10
Discussion.

11.10-11.30
Coffee break

11.30-12.10
Combined paediatric vaccines for national immunisation programmes. 1,631 Kb (.ppt)
Francis André (GlaxoSmithKline, Belgium)
HEXAVACÒ - A new liquid DTacP-IPV-Hib-HB hexavalent vaccine - Overview of its clinical profile. 286 Kb(.ppt)
Benoît Soubeyrand (Aventis Pasteur, France)

12.10–12.30
Discussion, including: Safety issues in the production of combined versus monovalent vaccines - Stocks of combined vaccines - How to encourage companies to produce combined vaccines? - …

12.30–14.00
Lunch

Session 5 Impact of introducing combined vaccines

Chair: Nicole Guérin and Andrei Lobanov 14.00-14.20
Economic aspects of combined vaccines. 59 Kb (.ppt)
Philippe Beutels (University of Antwerpen, Belgium)

14.20–15.20
Decision-making process and impact of implementation of hexavalent vaccines in national immunisation programmes: the case of Germany. 62 Kb (.ppt)
Wolfgang Jilg (University of Regensburg, Germany) Discussion, including: Why countries do or do not introduce combined vaccines - Impact of vaccines on the decision-making process.

15.20-15.40
Coffee break

Session 6 Conclusions of the meeting

Chair: Pierre Van Damme

15.40-16.40
Presentation of the VHPB conclusions. 46 Kb (.ppt)
David FitzSimons (WHO, Switzerland)

16.40-17.00
Closing of the meeting.

Tags: